Skip to Main Content

Health care giant Johnson & Johnson said Wednesday that it is acquiring Momenta Pharmaceuticals, gaining access to a promising experimental treatment for autoimmune diseases.

Momenta is being acquired for $52.50 per share, or a 73% premium to Tuesday’s closing price. The all-cash deal values the company at $6.5 billion.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!